Shahriari, F. Et Al. 2025. Hypericin and resveratrol anti‐tumor impact through E‐cadherin, N‐cadherin, galectin‐3, and BAX/BCL‐ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cells. PRECISION MEDICAL SCIENCES , vol.14 .

Shahriari, F., Barati, M., Shahbazi, S., Zaferani Arani, H., Dahmardnezhad, M., Javidi, M. A., ... ALİZADE, A.(2025). Hypericin and resveratrol anti‐tumor impact through E‐cadherin, N‐cadherin, galectin‐3, and BAX/BCL‐ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cells. PRECISION MEDICAL SCIENCES , vol.14.

Shahriari, Fatemeh Et Al. "Hypericin and resveratrol anti‐tumor impact through E‐cadherin, N‐cadherin, galectin‐3, and BAX/BCL‐ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cells," PRECISION MEDICAL SCIENCES , vol.14, 2025

Shahriari, Fatemeh Et Al. "Hypericin and resveratrol anti‐tumor impact through E‐cadherin, N‐cadherin, galectin‐3, and BAX/BCL‐ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cells." PRECISION MEDICAL SCIENCES , vol.14, 2025

Shahriari, F. Et Al. (2025) . "Hypericin and resveratrol anti‐tumor impact through E‐cadherin, N‐cadherin, galectin‐3, and BAX/BCL‐ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cells." PRECISION MEDICAL SCIENCES , vol.14.

@article{article, author={Fatemeh Shahriari Et Al. }, title={Hypericin and resveratrol anti‐tumor impact through E‐cadherin, N‐cadherin, galectin‐3, and BAX/BCL‐ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cells}, journal={PRECISION MEDICAL SCIENCES}, year=2025}